Xie Ke-Jie, He Hong-Er, Sun Ai-Jing, Liu Xi-Bo, Sun Li-Ping, Dong Xue-Jun
Clinical Examination Center, Shaoxing People's Hospital, Shaoxing Hospital of Zhejiang University, Shaoxing, China E-mail :
Asian Pac J Cancer Prev. 2014;15(6):2591-6. doi: 10.7314/apjcp.2014.15.6.2591.
To evaluate the prognostic value of the expression of excision repair cross-complementation group l (ERCC1), MutS protein homolog 2 (MSH2) and poly ADP-ribose polymerase 1 (PARP1) in non-small-cell lung cancer patients receiving platinum-based postoperative adjuvant chemotherapy.
Immunohistochemistry was applied to detect the expression of ERCC1, MSH2 and PARP1 in 111 cases of non-small cell lung cancer paraffin embedded surgical specimens. Through og-rank survival analysis, we evaluated the prognostic value of the ERCC1, MSH2, PARP1 and the related clinicopathological factors. COX regression analysis was used to determine whether ERCC1, MSH2 and PARP1 were independent prognostic factors.
In the enrolled 111 non-small cell lung cancer patients, the positive expression rate of ERCC1, MSH2 and RARP1 was 33.3%, 36.9% and 55.9%, respectively. ERCC1 (P<0.001) and PARP1 (P=0.033) were found to be correlated with the survival time while there was no correlation for MSH2 (P=0.298). Patients with both ERCC1 and PARP1 negative cancer had significantly longer survival time than those with ERCC1 (P=0.042) or PARP1 (P=0.027) positive alone. Similalry, the survival time of patients with both ERCC1 and PARP1 positive cancer was shorter than those with ERCC1 (P=0.048) or PARP1 (P=0.01) positive alone.
Patients with ERCC1 or PARP1 negative non-small cell lung cancer appear to benefit from platinum-based postoperative adjuvant chemotherapy.
评估切除修复交叉互补基因1（ERCC1）、错配修复蛋白同源物2（MSH2）和聚ADP核糖聚合酶1（PARP1）的表达在接受铂类术后辅助化疗的非小细胞肺癌患者中的预后价值。
应用免疫组织化学法检测111例非小细胞肺癌石蜡包埋手术标本中ERCC1、MSH2和PARP1的表达。通过对数秩生存分析，评估ERCC1、MSH2、PARP1及相关临床病理因素的预后价值。采用COX回归分析确定ERCC1、MSH2和PARP1是否为独立预后因素。
在纳入的111例非小细胞肺癌患者中，ERCC1、MSH2和PARP1的阳性表达率分别为33.3%、36.9%和55.9%。发现ERCC1（P<0.001）和PARP1（P=0.033）与生存时间相关，而MSH2与生存时间无关（P=0.298）。ERCC1和PARP1均为阴性的癌症患者的生存时间显著长于单独ERCC1阳性（P=0.042）或PARP1阳性（P=0.027）的患者。同样，ERCC1和PARP1均为阳性的癌症患者的生存时间短于单独ERCC1阳性（P=0.048）或PARP1阳性（P=0.01）的患者。
ERCC1或PARP1阴性的非小细胞肺癌患者似乎能从铂类术后辅助化疗中获益。
